1. Beaugerie L, Svrcek M, Seksik P, et al. Risk of colorectal high-grade dysplasia and cancer in a prospective observational cohort of patients with inflammatory bowel disease. Gastroenterology 2013;145:166-175.e8.PMID:
23541909.
2. Meyer AM, Ramzan NN, Loftus EV Jr, Heigh RI, Leighton JA. The diagnostic yield of stool pathogen studies during relapses of inflammatory bowel disease. J Clin Gastroenterol 2004;38:772-775.PMID:
15365403.
3. Jess T, Simonsen J, Nielsen NM, et al. Enteric Salmonella or Campylobacter infections and the risk of inflammatory bowel disease. Gut 2011;60:318-324.PMID:
21193449.
4. Pola S, Patel D, Ramamoorthy S, et al. Strategies for the care of adults hospitalized for active ulcerative colitis. Clin Gastroenterol Hepatol 2012;10:1315-1325.e4.PMID:
22835577.
5. Sartor RB. Microbial influences in inflammatory bowel diseases. Gastroenterology 2008;134:577-594.PMID:
18242222.
6. Schulfer AF, Battaglia T, Alvarez Y, et al. Intergenerational transfer of antibiotic-perturbed microbiota enhances colitis in susceptible mice. Nat Microbiol 2018;3:234-242.PMID:
29180726.
7. Ungaro R, Bernstein CN, Gearry R, et al. Antibiotics associated with increased risk of new-onset Crohn's disease but not ulcerative colitis: a meta-analysis. Am J Gastroenterol 2014;109:1728-1738.PMID:
25223575.
8. Högenauer C, Langner C, Beubler E, et al. Klebsiella oxytoca as a causative organism of antibiotic-associated hemorrhagic colitis. N Engl J Med 2006;355:2418-2426.PMID:
17151365.
9. Zollner-Schwetz I, Högenauer C, Joainig M, et al. Role of Klebsiella oxytoca in antibiotic-associated diarrhea. Clin Infect Dis 2008;47:e74-e78.PMID:
10.1086/592074. PMID:
18808355.
10. Sweetser S, Schroeder KW, Pardi DS. Pseudomembranous colitis secondary to Klebsiella oxytoca. Am J Gastroenterol 2009;104:2366-2368.PMID:
19727105.
11. Plessier A, Cosnes J, Gendre JP, Beaugerie L. Intercurrent Klebsiella oxytoca colitis in a patient with Crohn's disease. Gastroenterol Clin Biol 2002;26:799-800.PMID:
12434087.
12. Zollner-Schwetz I, Herzog KA, Feierl G, et al. The toxin-producing pathobiont Klebsiella oxytoca is not associated with flares of inflammatory bowel diseases. Dig Dis Sci 2015;60:3393-3398.PMID:
26091802.
13. Aroniadis OC, Brandt LJ, Greenberg A, et al. Long-term follow-up study of fecal microbiota transplantation for severe and/or complicated Clostridium difficile infection: a multicenter experience. J Clin Gastroenterol 2016;50:398-402.PMID:
26125460.
14. Jodorkovsky D, Young Y, Abreu MT. Clinical outcomes of patients with ulcerative colitis and co-existing Clostridium difficile infection. Dig Dis Sci 2010;55:415-420.PMID:
19255850.
15. Trnka YM, LaMont JT. Association of Clostridium difficile toxin with symptomatic relapse of chronic inflammatory bowel disease. Gastroenterology 1981;80:693-696.PMID:
7202941.
16. Meyers S, Mayer L, Bottone E, Desmond E, Janowitz HD. Occurrence of Clostridium difficile toxin during the course of inflammatory bowel disease. Gastroenterology 1981;80:697-670.PMID:
7202942.
17. Clayton EM, Rea MC, Shanahan F, et al. The vexed relationship between Clostridium difficile and inflammatory bowel disease: an assessment of carriage in an outpatient setting among patients in remission. Am J Gastroenterol 2009;104:1162-1169.PMID:
19319128.
18. Dorman SA, Liggoria E, Winn WC Jr, Beeken WL. Isolation of Clostridium difficile from patients with inactive Crohn's disease. Gastroenterology 1982;82:1348-1351.PMID:
7067956.
19. Polage CR, Gyorke CE, Kennedy MA, et al. Overdiagnosis of Clostridium difficile infection in the molecular test era. JAMA Intern Med 2015;175:1792-1801.PMID:
26348734.